Scout Campers' newest and largest pickup truck-mounted RV can sleep up to 6 people – see inside the $23,625 Kenai

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Scout Campers' Kenai. Scout CampersScout Campers, which specializes in off-grid hardshell pickup truck campers, has launched its newest and largest model: the Kenai. The $23,625 camper has a bathroom space, mudroom, and three designated sleeping areas with an optional roof tent. Several aspects of the Kenai are optional or customizable, including the toilet type and storage-related amenities. Visit Business Insider's homepage for more stories. Scout Campers, which specializes in off-grid pickup truck campers, has announced its third and largest model: the Kenai. The Washington-based company first launched in April with its Olympic camper and plans to later unveil two more models, the Yoho and Kenai. Two months later in late June, the Yoho was unveiled, making this recently announced Kenai camper the company's latest release.  All three campers have arrived on the market at a time in which both RV and camper van conversion companies have reported an increase in interest and sales despite the coronavirus pandemic's presence in the US. But unlike these RV and van-specific companies, Scout Campers takes advantage of pickup trucks, the country's most popular vehicle type, at a less expensive price compared to other tiny homes on wheels despite offering many of the same To keep reading about Scout Campers' newest and largest pickup truck-mounted RV can sleep up to 6 people – see inside the $23,625 Kenai, Click on the link. Seoul, Korea
http://dlvr.it/RpVM4s

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint